Summary
Methylglyoxal bis-guanylhydrazone (MGBG), a potent inhibitor of polyamine synthesis, has demonstrated single agent activity against a number of tumor types including malignant lymphomas and head and neck, esophageal and non-small cell lung cancers. The growth of small cell lung cancer (SCLC) cell lines can be arrested by polyamine inhibition. Therefore a phase II trial was conducted in twenty-four patients with refractory SCLC. MGBG was administered by intravenous infusion at a dose of 500 mg/m2 per week for four cycles and then every two weeks thereafter. The dose was escalated by 100 mg/m2 every two weeks in the absence of toxicity ⩾ grade 2. One patient achieved a partial response of objectively measurable lung disease and supraclavicular adenopathy. Three patients had stable disease. Dose limiting toxicity consisted primarily of mild to moderate nausea, vomiting, stomatitis and/or diarrhea. Myelosuppression was uncommon and rarely dose limiting. We conclude that MGBG in the dose and schedule used does not have significant activity as a single agent in previously treated small cell lung cancer.
Similar content being viewed by others
References
Warrell RP, Burchenal JH: Methylglyoxal-bis (guanylhydrazone) (methyl-GAG): Current status and future prospects. J Clin Oncol 1: 52–65, 1983
Pine MJ, Dipaolo JA: The antimitochondrial action of 2-chloro-4′,4″-bis (2-imidazolin-2-yl) terephthalanilide and methyl-glyoxal bis (guanyl hydrazone). Cancer Res 26: 18–25, 1966
Williams-Ashman HG, Scheone A: Methylglyoxal bis-(guanyl hydrazone) as a potent inhibitor of mammalian and yeast S-adenosylmethionine decarboxylases. Biochem Biophys Res Commun 46: 288–295, 1972
Pegg AE, McCann PP: Polyamine metabolism and function. Am J Physiol 243: C212-C221, 1982
Russell DH: Increased polyamine concentrations in the urine of human cancer patients. Nature (New Biol) 233: 144–145, 1971
Luk GD, Goodwin G, Marton LJ, Baylin SB: Polyamines are necessary for the survival of human small-cell lung carcinoma in culture. Proc Natl Acad Sci USA 78: 2355–2358, 1981
Knight WA, Livingstone RB, Fabian C, Constanzi J: Phase I–II trial of methyl-GAG: a southwest oncology group pilotstudy. Cancer Treat Rep 63: 1933–1937, 1979
Abeloff MD, Slavik M, Luk GD, Griffin CA, Hermann J, Blanc O, Sjoerdsma A, Baylin SB: Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine — an inhibitor of polyamine biosynthesis. J Clin Oncol 2: 124–130, 1984
Abeloff MD, Rosen ST, Luk GD, Baylin SB, Zeltzman M, Sjoerdsma A: Phase II Trials of alpha-difluromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer. Cancer Treat Rep 70: 843–845, 1986
Griffin CA, Slavik M, Chien SC, Hermann J, Thompson G, Blanc O, Luk GD, Baylin SB, Abeloff MD: Phase I trial and pharmacokinetic study of intravenous and oral alpha-di-fluoromethylornithine. Invest New Drugs 5: 177–186, 1987
Scher H, Chapman R, Kelsen D, Gralla R, Wittes R: Phase II trial of mitoguazone in patients with relapsed small cell carcinoma of the lung. Cancer Treat Rep 68: 561–562, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Simon, M.S., Eckenrode, J. & Natale, R.B. Phase II trial of methylglyoxal bis-guanylhydrazone (MGBG) in refractory small cell lung cancer. Invest New Drugs 8 (Suppl 1), S79–S81 (1990). https://doi.org/10.1007/BF00171989
Issue Date:
DOI: https://doi.org/10.1007/BF00171989